Pomerantz LLP filed a securities class action against Insulet Corporation and certain officers on July 2, 2026, alleging the company misled investors about manufacturing defects in its Omnipod insulin delivery systems. The lawsuit covers investors who purchased PODD shares between Feb. 21, 2025 and May 26, 2026. Insulet's stock fell 6.9% in March and another 5.1% in May after the company announced voluntary medical device corrections for manufacturing issues.
Pomerantz LLP filed a securities class action against Insulet Corporation and certain officers on July 2, 2026, alleging the company misled investors about manufacturing defects in its Omnipod insulin delivery systems. The lawsuit covers investors who purchased PODD shares between Feb. 21, 2025 and May 26, 2026. Insulet's stock fell 6.9% in March and another 5.1% in May after the company announced voluntary medical device corrections for manufacturing issues.
Pomerantz LLP sued Insulet Corp. over alleged securities fraud, saying the insulin pump maker hid manufacturing defects that triggered two product recalls.
"Insulet's manufacturing controls were defective, creating a foreseeable risk that its products would violate safety regulations," the complaint filed in the U.S. District Court for the District of Massachusetts alleges.
The class action covers investors who bought PODD shares from Feb. 21, 2025 through May 26, 2026. On March 12, 2026, Insulet disclosed a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods. The stock fell $16.23, or 6.9%, to $219.84 the next day. On May 26, the company announced a second correction for Omnipod 5, Omnipod Dash and Omnipod Eros pods due to a manufacturing issue that could cause insulin under-delivery. Shares dropped another $7.79, or 5.1%, to $146.01.
The lawsuit seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors have until Aug. 31, 2026 to file a lead plaintiff motion.
Law Offices of Howard G. Smith and Robbins LLP have also announced investigations into similar claims. The case is docketed as 26-cv-13062 in the District of Massachusetts.
The lawsuit adds legal risk to Insulet's operational challenges after two recalls in three months. Investors will watch for the lead plaintiff appointment and any further disclosures about the scope of the manufacturing defects.
This article is for informational purposes only and does not constitute investment advice.
